Rodríguez Márquez’s statements come a day after he announced from the headquarters of the American laboratory, like the Russian Direct Investment Fund (RDIF) that financed Sputnik V, that they have already begun to work on a new version of those immunizers against the coronavirus especially aimed at neutralizing the new variant.
Likewise, both developers considered it unlikely that their current vaccines are not effective against the mutation.
The Nikolai Gamaleya Center for Epidemiology and Microbiology, the agency that manufactured Sputnik V, “has already proceeded to develop a new version of the Sputnik vaccine, adapted to the Omicron variant,” RDIF said in a statement.
For his part, the general director of the Janssen pharmaceutical company in Spain and Portugal, Luis Díaz-Rubio Amate, announced today that his company is “testing” the effectiveness of its vaccine against Ómicron, with the possibility of producing a “specific one if it were necessary”.
“We are currently intensively monitoring new strains, such as Ómicron, which has been causing so much concern in recent days. It generates variations in the protein sequence”added the director general during his speech before the Commission for the Investigation of vaccines and the Vaccination Plan of the Spanish Congress of Deputies.
The Janssen leader added that the pharmaceutical company is “working together with the World Health Organization (WHO), the academic world and different institutions” to clarify what the impact of Ómicron could be on already approved vaccines.
In any case, Díaz-Rubio Amate defended that Janssen “continues to believe in the benefit” of its vaccine, which is provided non-profit for the duration of the pandemic, “to millions of people around the world.”
On the other hand, the businessman acknowledged today that it is “complex” to transfer vaccine technology so that it can be carried out by other centers around the world.
“It is complex due to the needs of equipment, raw materials. Technology transfer is a complex project that requires qualified personnel with great experience,” he explained.
Despite this, he said that “having access to life-saving vaccines should not depend on where you live or purchasing power.”
“We are especially proud of our work to facilitate equitable access,” he claimed
Source From: Ambito
David William is a talented author who has made a name for himself in the world of writing. He is a professional author who writes on a wide range of topics, from general interest to opinion news. David is currently working as a writer at 24 hours worlds where he brings his unique perspective and in-depth research to his articles, making them both informative and engaging.
